Trends in the global healthcare market. Development of pharmaceuticals, market data and insights.
Presentation delivered at the 9th International Pharmaceutical Compliance Congress and Best Practices Forum, Brussels, 2015
Generic medicines play an essential role in increasing access to affordable medicines. They currently make up over half of all medicines by volume but only 18% of costs, and have generated €30 billion in savings for EU healthcare systems. However, greater utilization of generic medicines could double these savings. For generics to continue providing benefits, policies must ensure fair prices, a level playing field, and acceptable margins across the supply chain.
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
What can we do to ensure that patients have the medicines they need? FernandoLamata
Thousands of people suffer and die because they don't have access to medicines. The main cause of this problem is that prices of medicines are too high, are abusive.
Different actions that governments can adopt to improve access to medicines
The document discusses the Moroccan medical device market and Eramedic's vision. It provides key facts about Morocco's population, economy, health expenditures, and medical device imports and market trends. The medical device market is growing but still small compared to global markets. Eramedic aims to promote new concepts, competitive products, and innovative offers while strengthening partnerships and expanding its regional and international reach.
Prescription Medicines - Costs in Context - May 2018PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending in the US and globally, innovative new medicines are transforming care for chronic diseases. While generic drugs now make up 90% of prescriptions filled in the US, brand drug prices have grown just 1.9% after rebates and discounts are applied. The document argues that competition from generics and biosimilars will reduce brand drug sales, but innovator companies continue developing new medicines to treat diseases.
Prescription Medicines - Costs in Context - August 2018PhRMA
Discussions about the cost and affordability of medicines – and health care more broadly – are important. At the same time, it is important to look at costs across the health care system and not just the share going toward life changing medicines.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Generic medicines play an essential role in increasing access to affordable medicines. They currently make up over half of all medicines by volume but only 18% of costs, and have generated €30 billion in savings for EU healthcare systems. However, greater utilization of generic medicines could double these savings. For generics to continue providing benefits, policies must ensure fair prices, a level playing field, and acceptable margins across the supply chain.
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
What can we do to ensure that patients have the medicines they need? FernandoLamata
Thousands of people suffer and die because they don't have access to medicines. The main cause of this problem is that prices of medicines are too high, are abusive.
Different actions that governments can adopt to improve access to medicines
The document discusses the Moroccan medical device market and Eramedic's vision. It provides key facts about Morocco's population, economy, health expenditures, and medical device imports and market trends. The medical device market is growing but still small compared to global markets. Eramedic aims to promote new concepts, competitive products, and innovative offers while strengthening partnerships and expanding its regional and international reach.
Prescription Medicines - Costs in Context - May 2018PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending in the US and globally, innovative new medicines are transforming care for chronic diseases. While generic drugs now make up 90% of prescriptions filled in the US, brand drug prices have grown just 1.9% after rebates and discounts are applied. The document argues that competition from generics and biosimilars will reduce brand drug sales, but innovator companies continue developing new medicines to treat diseases.
Prescription Medicines - Costs in Context - August 2018PhRMA
Discussions about the cost and affordability of medicines – and health care more broadly – are important. At the same time, it is important to look at costs across the health care system and not just the share going toward life changing medicines.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Pharmaceutical pricing and reimbursement usaNeha Kalal
This document provides an overview of pharmaceutical pricing and reimbursement in the United States. It discusses key demographics and economic factors, the major public and private healthcare programs, and how drug pricing and reimbursement works. The US healthcare system is complex, with prescription drugs constituting 12% of total spending. Major public programs include Medicare, Medicaid, and CHIP, while private sources include employer and individual insurance plans. Pharmaceutical companies set prices freely, while payers determine reimbursement levels and use formularies, tiers, and cost-sharing to manage drug costs.
Business opportunities in private hospital sector in indiaBusiness Finland
The document summarizes business opportunities in India's private hospital sector. It notes that the healthcare industry in India is growing rapidly at 20% annually and is expected to reach $100 billion by 2015. The private sector accounts for 65% of hospital beds and 80% of healthcare spending, and is growing at 24.1% annually. Opportunities exist for foreign companies in areas like medical equipment, diagnostic devices, health IT, and green building technologies. The largest private hospital chains in India are outlined. Fast growing specialty areas include oncology, orthopedics, and cardiology.
The document provides an overview of the diagnostics market in Asia. It notes that the market is expected to grow at a CAGR of 8.5% between 2007-2008 due to factors such as increasing healthcare spending, aging populations, and demand for preventative healthcare tools. The largest regional markets are China, India, and Japan, though all markets are expected to see steady growth. The largest product segments are clinical chemistry, immuno-chemistry, and self-monitoring blood glucose devices.
Case for emerging 9 sustaining oncology innovationyuvrajgill
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
The Medicines Patent Pool Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
The document provides an overview of the diagnostics market in Asia from 2009-2010. It finds that the market is expected to grow at a CAGR of 8.5% due to factors like an aging population, increasing healthcare spending, and a shift toward preventative care. The largest national markets are China, expected to grow at 14.5% CAGR, and India at 12.1% CAGR. Leading segments are immunoassay, clinical chemistry and self-monitoring of blood glucose. Emerging areas of growth include molecular diagnostics, point-of-care testing and laboratory automation.
This document discusses the business opportunity in Kenya for diabetes equipment. It notes that the East African region has a population of around 250 million people across 6 countries. The rates of urbanization and lifestyle diseases like diabetes are increasing as incomes rise in the growing middle class. There is a need for modern diabetes equipment and technologies, as products are currently imported but not locally manufactured. Finnish companies that produce screening, diagnostic, treatment and monitoring equipment would find opportunities in the private and public healthcare sectors of Kenya and the broader East African market.
The growing 50+ market, driven by the demand and spending power of the baby boomer generations, is changing the global economy and also offers big opportunities for Finnish companies.
Czech Republic Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mu...ReportsnReports
This document provides a summary of a 175-page report on the Czech Republic patient monitoring market outlook from 2012 to 2018. The report segments the market into fetal monitors, multiparameter patient monitoring, neonatal monitors, non-invasive blood pressure monitors, patient monitoring accessories, and remote patient monitoring. It provides historical and forecasted market data on revenue, volume, and average price for each segment. It also includes company share and distribution share data. The full report is available for purchase for $2,500 and contains additional profiles of key market players and pipeline products.
Denmark Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multipara...ReportsnReports
This document provides a 173-page report on the Denmark patient monitoring market outlook from 2012 to 2018. It includes market segmentation data, revenue and volume forecasts, average pricing, and company market shares for various patient monitoring product categories including fetal monitors, multiparameter monitors, neonatal monitors, non-invasive blood pressure monitors, and others. Major companies covered in the report include Philips Healthcare, GE Healthcare, and Draegerwerk AG & Co. KGaA. The report is based on proprietary research and is intended to help readers develop business and market strategies for the Denmark patient monitoring industry.
5 Trends to Watch in the Medical Device Industry in 2016Mercer Capital
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for incumbent products, a growing global market provides domestic device manufacturers with an opportunity to broaden and diversify their geographic revenue base. Developing new products and procedures is risky and usually more resource intensive compared to some other growth sectors of the economy. However, barriers to entry in the form of existing regulations provide a measure of relief from competition, especially for newly developed products.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2016 | Pfizer...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Each issue includes a segment focus, market overview, mergers and acquisitions review, and more.
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Office of Health Economics
This presentation summarises the results of experts interviews aiming to identify the key factors which have influenced the access and the uptake of direct acting antivirals (DAAs) in selected European countries. This qualitative piece of analysis was conducted as part of a larger project studying the development and the diffusion of innovation in the market of treatments for hepatitis C. The interviews shed light on the reimbursement strategies and other factors, relating to the ability of individual health care systems to supply the treatments, which may have influenced, positively of negatively, access and speed of uptake of DAAs in Europe.
Author(s) and affiliation(s): Margherita Neri, Office of Health Economics; Mikel Berdud, Office of Health Economics; Martina Garau, Office of Health Economics; Phill O’Neill, Office of Health Economics; Chris Sampson, Office of Health Economics; Adrian Towse, Office of Health Economics.
Conference/meeting: EuHEA Conference 2018
Location: Maastricht, Netherlands
Date: 11/07/2018
Opportunities in the dental sector in emerging asian markets and india finproBusiness Finland
This document discusses business opportunities for Finnish dental companies in emerging Asian markets. It finds that the dental sectors in China, India, Taiwan, and Malaysia are growing rapidly due to an expanding middle class and increased focus on dental health. The number of dentists and dental clinics is rising in all countries. All countries import most high-end dental equipment from Europe, Japan, and the US, representing an opportunity for Finnish exporters. The dental market is worth $400 million in China and growing at 21% annually, while India's market is expected to reach $116 million by 2014 at 6% growth. Taiwan and Malaysia also represent opportunities as their markets grow over 10% annually and have relatively light regulations for foreign dental products and equipment.
The document provides an overview of the Vietnam healthcare market. It discusses opportunities in the growing hospital sector, including potential partnerships between local and foreign companies. It also outlines opportunities in pharmaceuticals and medical devices, noting Vietnam's goal of becoming a regional production hub by 2020. The private hospital sector is expanding due to government policies promoting privatization and foreign investment in healthcare infrastructure.
The document provides an in-depth 72-page report on the pharmaceutical market in Canada. It includes five-year projections of economic, demographic and pharmaceutical market indicators. It summarizes that the Canadian pharmaceutical market is projected to grow steadily through 2016 due to an aging population and commitment to healthcare, though government spending constraints could impact growth. It also notes that Canada has a strong domestic generic industry and pharmaceutical exports exceed $6 billion annually, driven partly by parallel trade with the US.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
The Vietnamese pharmaceutical market was valued at VND80,679 billion in 2014 and is expected to grow at a compound annual growth rate of 15.1% to reach VND139,832 billion by 2018. Currently over 50% of domestic demand is met through imports as domestic firms face competition from foreign companies with more advanced technology. However, Vietnam's growing and increasingly health-conscious population represents opportunities for future growth in the pharmaceutical industry. The top 10 listed pharmaceutical companies in Vietnam by market share are led by Vimedimex Medi-Pharma with a 14.6% share.
The document discusses cost containment strategies in health systems in Europe, the United States, and the United Kingdom. In Europe, health spending and performance varies widely by country. While total spending correlates somewhat with life expectancy, the public-private split does not seem to directly impact performance. In the US, consistent performers at containing costs emphasize quality care, financial incentives, health improvement, and data-driven decision making. Many successful companies have adopted consumer-driven health plans. In the UK, insurers focus on remaining competitive while employers prioritize other benefits; the NHS is exploring more public-private partnerships and giving patients more choice and control.
Pharmaceutical pricing and reimbursement usaNeha Kalal
This document provides an overview of pharmaceutical pricing and reimbursement in the United States. It discusses key demographics and economic factors, the major public and private healthcare programs, and how drug pricing and reimbursement works. The US healthcare system is complex, with prescription drugs constituting 12% of total spending. Major public programs include Medicare, Medicaid, and CHIP, while private sources include employer and individual insurance plans. Pharmaceutical companies set prices freely, while payers determine reimbursement levels and use formularies, tiers, and cost-sharing to manage drug costs.
Business opportunities in private hospital sector in indiaBusiness Finland
The document summarizes business opportunities in India's private hospital sector. It notes that the healthcare industry in India is growing rapidly at 20% annually and is expected to reach $100 billion by 2015. The private sector accounts for 65% of hospital beds and 80% of healthcare spending, and is growing at 24.1% annually. Opportunities exist for foreign companies in areas like medical equipment, diagnostic devices, health IT, and green building technologies. The largest private hospital chains in India are outlined. Fast growing specialty areas include oncology, orthopedics, and cardiology.
The document provides an overview of the diagnostics market in Asia. It notes that the market is expected to grow at a CAGR of 8.5% between 2007-2008 due to factors such as increasing healthcare spending, aging populations, and demand for preventative healthcare tools. The largest regional markets are China, India, and Japan, though all markets are expected to see steady growth. The largest product segments are clinical chemistry, immuno-chemistry, and self-monitoring blood glucose devices.
Case for emerging 9 sustaining oncology innovationyuvrajgill
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
The Medicines Patent Pool Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
The document provides an overview of the diagnostics market in Asia from 2009-2010. It finds that the market is expected to grow at a CAGR of 8.5% due to factors like an aging population, increasing healthcare spending, and a shift toward preventative care. The largest national markets are China, expected to grow at 14.5% CAGR, and India at 12.1% CAGR. Leading segments are immunoassay, clinical chemistry and self-monitoring of blood glucose. Emerging areas of growth include molecular diagnostics, point-of-care testing and laboratory automation.
This document discusses the business opportunity in Kenya for diabetes equipment. It notes that the East African region has a population of around 250 million people across 6 countries. The rates of urbanization and lifestyle diseases like diabetes are increasing as incomes rise in the growing middle class. There is a need for modern diabetes equipment and technologies, as products are currently imported but not locally manufactured. Finnish companies that produce screening, diagnostic, treatment and monitoring equipment would find opportunities in the private and public healthcare sectors of Kenya and the broader East African market.
The growing 50+ market, driven by the demand and spending power of the baby boomer generations, is changing the global economy and also offers big opportunities for Finnish companies.
Czech Republic Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mu...ReportsnReports
This document provides a summary of a 175-page report on the Czech Republic patient monitoring market outlook from 2012 to 2018. The report segments the market into fetal monitors, multiparameter patient monitoring, neonatal monitors, non-invasive blood pressure monitors, patient monitoring accessories, and remote patient monitoring. It provides historical and forecasted market data on revenue, volume, and average price for each segment. It also includes company share and distribution share data. The full report is available for purchase for $2,500 and contains additional profiles of key market players and pipeline products.
Denmark Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multipara...ReportsnReports
This document provides a 173-page report on the Denmark patient monitoring market outlook from 2012 to 2018. It includes market segmentation data, revenue and volume forecasts, average pricing, and company market shares for various patient monitoring product categories including fetal monitors, multiparameter monitors, neonatal monitors, non-invasive blood pressure monitors, and others. Major companies covered in the report include Philips Healthcare, GE Healthcare, and Draegerwerk AG & Co. KGaA. The report is based on proprietary research and is intended to help readers develop business and market strategies for the Denmark patient monitoring industry.
5 Trends to Watch in the Medical Device Industry in 2016Mercer Capital
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for incumbent products, a growing global market provides domestic device manufacturers with an opportunity to broaden and diversify their geographic revenue base. Developing new products and procedures is risky and usually more resource intensive compared to some other growth sectors of the economy. However, barriers to entry in the form of existing regulations provide a measure of relief from competition, especially for newly developed products.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2016 | Pfizer...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Each issue includes a segment focus, market overview, mergers and acquisitions review, and more.
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Office of Health Economics
This presentation summarises the results of experts interviews aiming to identify the key factors which have influenced the access and the uptake of direct acting antivirals (DAAs) in selected European countries. This qualitative piece of analysis was conducted as part of a larger project studying the development and the diffusion of innovation in the market of treatments for hepatitis C. The interviews shed light on the reimbursement strategies and other factors, relating to the ability of individual health care systems to supply the treatments, which may have influenced, positively of negatively, access and speed of uptake of DAAs in Europe.
Author(s) and affiliation(s): Margherita Neri, Office of Health Economics; Mikel Berdud, Office of Health Economics; Martina Garau, Office of Health Economics; Phill O’Neill, Office of Health Economics; Chris Sampson, Office of Health Economics; Adrian Towse, Office of Health Economics.
Conference/meeting: EuHEA Conference 2018
Location: Maastricht, Netherlands
Date: 11/07/2018
Opportunities in the dental sector in emerging asian markets and india finproBusiness Finland
This document discusses business opportunities for Finnish dental companies in emerging Asian markets. It finds that the dental sectors in China, India, Taiwan, and Malaysia are growing rapidly due to an expanding middle class and increased focus on dental health. The number of dentists and dental clinics is rising in all countries. All countries import most high-end dental equipment from Europe, Japan, and the US, representing an opportunity for Finnish exporters. The dental market is worth $400 million in China and growing at 21% annually, while India's market is expected to reach $116 million by 2014 at 6% growth. Taiwan and Malaysia also represent opportunities as their markets grow over 10% annually and have relatively light regulations for foreign dental products and equipment.
The document provides an overview of the Vietnam healthcare market. It discusses opportunities in the growing hospital sector, including potential partnerships between local and foreign companies. It also outlines opportunities in pharmaceuticals and medical devices, noting Vietnam's goal of becoming a regional production hub by 2020. The private hospital sector is expanding due to government policies promoting privatization and foreign investment in healthcare infrastructure.
The document provides an in-depth 72-page report on the pharmaceutical market in Canada. It includes five-year projections of economic, demographic and pharmaceutical market indicators. It summarizes that the Canadian pharmaceutical market is projected to grow steadily through 2016 due to an aging population and commitment to healthcare, though government spending constraints could impact growth. It also notes that Canada has a strong domestic generic industry and pharmaceutical exports exceed $6 billion annually, driven partly by parallel trade with the US.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
The Vietnamese pharmaceutical market was valued at VND80,679 billion in 2014 and is expected to grow at a compound annual growth rate of 15.1% to reach VND139,832 billion by 2018. Currently over 50% of domestic demand is met through imports as domestic firms face competition from foreign companies with more advanced technology. However, Vietnam's growing and increasingly health-conscious population represents opportunities for future growth in the pharmaceutical industry. The top 10 listed pharmaceutical companies in Vietnam by market share are led by Vimedimex Medi-Pharma with a 14.6% share.
The document discusses cost containment strategies in health systems in Europe, the United States, and the United Kingdom. In Europe, health spending and performance varies widely by country. While total spending correlates somewhat with life expectancy, the public-private split does not seem to directly impact performance. In the US, consistent performers at containing costs emphasize quality care, financial incentives, health improvement, and data-driven decision making. Many successful companies have adopted consumer-driven health plans. In the UK, insurers focus on remaining competitive while employers prioritize other benefits; the NHS is exploring more public-private partnerships and giving patients more choice and control.
This report explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price negotiations with the pharmaceutical industry? Are national guidelines being adhered to in shaping France’s healthcare delivery?
Investigation of the accessibility and affordability of medicines in speciali...Cornelis Jan Diepeveen
The document discusses a study investigating the accessibility and affordability of medicines in specialist medical care in the Netherlands. It provides context on key players in the supply chain and financing of these medicines. The study included interviews, literature reviews, surveys, and data analysis. It examines current expenditures on these medicines, how costs may develop, and ways to better ensure accessibility and affordability. The summary provides high-level information on the purpose, methodology, and focus of the study without copying significant text.
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
As the biggest industry sector in most European economies, healthcare is already given a big chunk of the gross domestic product (GDP). This portion is expected to become even bigger and have a huge impact on employment, the opportunities to grow businesses and economies in general.
Healthcare, from Products to Solutions Exploring some of the latest initiativ...Alix Aubert
with high-level healthcare executives. Today, through Life Science Talks, we have decided to make some of this information available
to the professional community at large, provided it is non-confidential, of public interest, and likely to spark interesting partnerships in
the future.
This white paper therefore condenses data drawn from a number of informative meetings with decision makers in the European
healthcare sector during 2013 and 2014. More specifically, it is the result of an edition of Life science Talks dedicated to this subject
and held in Paris, in May 2014.
The discussions at this event were admirably moderated by Silvia Ondategui Parra, partner at EY, and were punctuated by keynotes
from leading stakeholders in European healthcare: Emmanuel Gomez, CNAM-TS, Head of Disease Management Programmes; Dr Rick
Greville, ABPI, Director of Wales and International Affairs; Thierry Zylberberg, Orange, Head of Orange Healthcare; Miguel Bernabeu,
Alcon (Novartis), Global Head of Market Access, Pricing and HEOR; Yvoine McCourt, Air Liquide, Head of Home Healthcare
International Development; Olivier Croly, GE Healthcare IT, GM Europe. Again, we thank them for sharing their views, their concerns,
and for outlining their projects in Europe within our forum.
Hampered with faltering economies, squeezed budgets
and aging populations, the healthcare systems of Europe’s
major markets are firmly focused on providing cost-effective
outcomes. Although each country has specific market access
requirements, Health Technology Assessment (HTA) has
become an essential input into pricing and reimbursement
decisions and clinical guidance on the use of innovative
technologies across Europe.
Though HTA practices differ across and within national
boundaries, specific themes have emerged.In particular,
demands for evidence of clinical and/or economic benefit on
new health technologies are increasing.
Pricing and reimbursement negotiations are becoming
increasingly difficult, as cost-containment strategies—
including reference pricing, limiting reimbursement for
drugs assessed to lack cost-effectiveness, and retroactively
assessing drugs already on the market—are being
implemented in various ways across Europe.
This document has been put together with our leading market access experts compiled together from number of primary research published by our team recently.
Feel free to reach out on msheikh@teamdrg.com if you would like to talk more about our analysis in this space and how we could support with any specific questions you may have.
About US: DRG's Research and Data portfolio delivers industry-leading primary research and insights. We provide our customers with a baseline for market intelligence.
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.
This document discusses prevention and health promotion in healthcare across Europe. It defines what good prevention and health promotion looks like, including health education programs, adult and child immunization policies, disease screening programs, infection prevention policies, and improving secondary prevention through risk factor reduction. The document emphasizes that while policymakers acknowledge the need to shift focus to prevention, progress has been variable. It argues that prevention is a cost-effective investment that can improve health and reduce disease burden and health inequalities.
Evaluation of health technologies in France: from theory to practice cheweb1
1) The document discusses economic evaluation of health technologies in France, outlining reforms that have strengthened the role of the French National Health Board (HAS) in conducting economic assessments.
2) Reforms in 2008 and 2012 gave HAS legal authority to produce economic guidance on pricing for new technologies alongside its clinical assessments.
3) HAS now produces efficiency guidance within 90 days of new technology submissions to inform pricing decisions, assessing expected cost-effectiveness and budget impact.
Ομιλία - Παρουσίαση: “The Value of Innovation to Patients & Health Systems”
Clare Hague PhD, Therapy Area Market Access Leader for Hematology, Janssen EMEA Region
1. The document discusses opportunities for new therapies in the treatment of posterior segment disorders such as dry age-related macular degeneration (AMD), diabetic macular edema (DME), and others.
2. It finds that dry AMD represents a significant market opportunity as the first drug to successfully target and prevent progression of geographic atrophy would have a major impact, given the large patient population and lack of current treatment options.
3. Key considerations for clinical development include using change in best corrected visual acuity or rate of geographic atrophy progression as the primary endpoint, enrolling patients with intermediate disease severity for at least 2 years, and demonstrating at least a 3-line difference in visual acuity or 20% reduction in
Fiscal sustainability of health systems - Chris James & Camila Vammalle, OECDOECD Governance
This presentation was made by Chris James and Camila Vammalle, OECD, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems held in Paris, on 16-17 February 2015.
This document summarizes a presentation given by David Lin from Novartis Oncology on drug purchasing and pricing from the pharmaceutical industry perspective. The presentation covers:
- The growing demand for healthcare and new treatments putting pressure on pricing and access
- Malaysia's national medicine policy and efforts to improve access to medicines through affordability
- Factors considered in pharmaceutical pricing like production costs, reference pricing to other countries, and balancing access and sustainability
- Efforts by industry like access programs to help patients gain early access to innovative treatments
- The changing treatment landscape with new cellular and personalized therapies requiring new frameworks for evaluation and pricing assessment.
Establish Pharmacovigilance Centres in hospital and National Programmes.pptxPiyushZala5
Three key points:
1) Pharmacovigilance centers play an important role in both hospitals and the pharmaceutical industry by monitoring adverse drug reactions and ensuring drug safety.
2) Establishing a pharmacovigilance center requires obtaining approvals, developing reporting forms, educating staff, creating a database to store reports, and networking with other organizations.
3) India has established a national pharmacovigilance program called PvPI coordinated by the Indian Pharmacopoeia Commission to monitor drug safety, expand reporting nationwide, and collaborate with other health programs.
Reimbursement and pricing strategies for drugs for ultra rare diseases: What can Canada learn from experiences across the pond?
Tania Stafinski, University of Alberta
Rare Disease Day Conference 2020 March 9-10
The world's population is growing larger, older, and sicker, placing increasing challenges on healthcare systems to expand access to care with finite resources. Chronic diseases now account for 70% of illnesses, and the population over 50 will increase by over 500 million by 2025. Healthcare systems face constraints like aging populations, growing disease burdens, and limited budgets. However, new medical technologies in development and advances in data analytics provide optimism for healthier futures. Key questions remain around how to introduce high-value innovations and make systems more sustainable.
The role of health technology assessment bodies in the value of cancer care i...Francois MAIGNEN
This presentation details the role of European HTA bodies in the value of new cancer therapies in Europe. The presentation also describes the NICE scientific advice activities and the activities of the HTA / regulatory parallel advice.
Similar to The data and analytics of the new life sciences marketplace handout (20)
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
2024 HIPAA Compliance Training Guide to the Compliance OfficersConference Panel
Join us for a comprehensive 90-minute lesson designed specifically for Compliance Officers and Practice/Business Managers. This 2024 HIPAA Training session will guide you through the critical steps needed to ensure your practice is fully prepared for upcoming audits. Key updates and significant changes under the Omnibus Rule will be covered, along with the latest applicable updates for 2024.
Key Areas Covered:
Texting and Email Communication: Understand the compliance requirements for electronic communication.
Encryption Standards: Learn what is necessary and what is overhyped.
Medical Messaging and Voice Data: Ensure secure handling of sensitive information.
IT Risk Factors: Identify and mitigate risks related to your IT infrastructure.
Why Attend:
Expert Instructor: Brian Tuttle, with over 20 years in Health IT and Compliance Consulting, brings invaluable experience and knowledge, including insights from over 1000 risk assessments and direct dealings with Office of Civil Rights HIPAA auditors.
Actionable Insights: Receive practical advice on preparing for audits and avoiding common mistakes.
Clarity on Compliance: Clear up misconceptions and understand the reality of HIPAA regulations.
Ensure your compliance strategy is up-to-date and effective. Enroll now and be prepared for the 2024 HIPAA audits.
Enroll Now to secure your spot in this crucial training session and ensure your HIPAA compliance is robust and audit-ready.
https://conferencepanel.com/conference/hipaa-training-for-the-compliance-officer-2024-updates
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfDr Rachana Gujar
The "Comprehensive Rainy Season Advisory: Safety and Preparedness Tips" offers essential guidance for navigating rainy weather conditions. It covers strategies for staying safe during storms, flood prevention measures, and advice on preparing for inclement weather. This advisory aims to ensure individuals are equipped with the knowledge and resources to handle the challenges of the rainy season effectively, emphasizing safety, preparedness, and resilience.
The data and analytics of the new life sciences marketplace handout
1. The Data and Analytics of
the New Life Sciences
Marketplace
9th International Pharmaceutical Compliance
Congress and Best Practices Forum
Dr. Frank Wartenberg
President Central Europe
13. Mai 2015